The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed.

Original languageEnglish (US)
Pages (from-to)221-223
Number of pages3
JournalClinical Lung Cancer
Volume7
Issue number3
DOIs
StatePublished - Jan 1 2005

Fingerprint

Mitogens
Lung Neoplasms
Phosphotransferases
MAP Kinase Kinase Kinases
Mutation
Mitogen-Activated Protein Kinase Kinases
Carcinogenesis
Therapeutics
Maintenance
Phenotype
Lung
Genes
Neoplasms

Keywords

  • MAP kinase
  • Mutations
  • Raf
  • Ras
  • Signaling pathways

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. / Adjei, Alex.

In: Clinical Lung Cancer, Vol. 7, No. 3, 01.01.2005, p. 221-223.

Research output: Contribution to journalReview article

@article{5ba4663618ad491599a086d5361a13a1,
title = "The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy",
abstract = "The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed.",
keywords = "MAP kinase, Mutations, Raf, Ras, Signaling pathways",
author = "Alex Adjei",
year = "2005",
month = "1",
day = "1",
doi = "10.3816/CLC.2005.n.040",
language = "English (US)",
volume = "7",
pages = "221--223",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy

AU - Adjei, Alex

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed.

AB - The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed.

KW - MAP kinase

KW - Mutations

KW - Raf

KW - Ras

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=33244482181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244482181&partnerID=8YFLogxK

U2 - 10.3816/CLC.2005.n.040

DO - 10.3816/CLC.2005.n.040

M3 - Review article

VL - 7

SP - 221

EP - 223

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -